Connect with us

Medical Discovery

Discovery Health – Stories of Survival – Facial Trauma

Published

on

Continue Reading
22 Comments

22 Comments

  1. hellknightofhell

    June 22, 2007 at 6:31 am

    I am now wery careful dont want to get in accidents like this

  2. Nancy Montella

    August 19, 2007 at 1:59 am

    they did good..:)

  3. bluewhale18

    October 16, 2007 at 12:06 pm

    just amazing what dr's can do these days

  4. SYED ABU KOYA Mag

    October 31, 2007 at 6:04 pm

    what shall i say..the doc was an angel from heaven!!lucky raul!! my u have a long life and live happily!

  5. niina

    December 19, 2007 at 12:36 am

    i got all teary eyed. i'm so happy for him. thank god for doctors and nurses to take care of us. really makes you feel how good the world can be.

  6. JohnACalero

    February 6, 2008 at 2:26 am

    wooow….he got really lucky …and the new technology for medicine always worth the risk

  7. MirMir

    March 17, 2008 at 8:11 am

    00:36, ow ow ow…..the blood blood blood show as we call it at home lives up to ti's name haha lol

  8. johnnyluver178

    October 24, 2008 at 9:49 pm

    sorry but i could never be a doctor or medical nurse/doctor i would throw up looking at things like that

  9. Danee Joy

    March 23, 2009 at 8:06 pm

    I would love to be a doctor and save lives if it wasnt for the fact i get so nausea so easy……the sight of blood on a cut makes me lightheaded and sick

  10. Nurul Hafiez Fijasri

    April 22, 2009 at 6:45 pm

    wow, i gonna get my MD for a couple of years and gonna go straight to surgery..it's so cool

  11. Charlie Sea

    April 24, 2009 at 11:12 pm

    we can use that platelet gel in the future in the war with the robots.
    totally kidding lol. its possible though rofl

  12. Dylan

    May 15, 2010 at 2:19 am

    If someone passed out in my arms I'd be like "Ew, gross.." and drop them.

  13. Walter

    June 22, 2010 at 3:38 pm

    @Emilinepinkie If you don't want the stress and crappy lifestyle of a Medical Doctor,become a Vet.
    Most Specialists work over 80 hours/week,can't live a proper relationship,can't see their kids,bring them to school,pick'em up,they can't even have fun with all the money they make,it requires a lot of committment.

  14. frincon75

    January 18, 2011 at 2:23 am

    i was at the hospital today and met this man he looked so good you could hardly tell he had all that done to him. GOD is good.

  15. theDirtyGupta01

    March 18, 2011 at 2:32 am

    @crazzioveru23 Yeah that's the idea, if that brain dead retard crashed into me I'd be close 2 killing the dumb son of a bitch. And 4 fucktards like @TheRackleman and others to make jokes about it I'd think it would b more funny if U were hit by that SUV.

  16. mode ostaz

    March 19, 2011 at 10:35 am

    i always say dentist is not only a dentist , dentist can ve surgeon or can be scientist 🙂

  17. TheJenOral

    July 6, 2012 at 9:44 pm

    Imagine that. U feel that u look better after a ladder smashes ur face to bits and a doctor puts u together properly. Poor dude.

  18. redpinkday

    November 11, 2013 at 3:53 am

    Want to be a nurse. Maybe in the operating room, don't know yet.

  19. Luar Zedlav

    December 13, 2013 at 5:38 pm

    WOW… THAT'S A GREAT MEDICAL JOB!!!  I'M JUST WANDERING BESIDES GETTING PHYSICAL "OK" THIS POOR GUY DOING WELL MENTALLY? I MEAN SINCE HE GOT HIT REALLY HARD IN HIS HEAD……..

  20. Thinh Duong

    February 11, 2016 at 11:48 pm

    Wow….   I mean WOW!!!  Good Luck Bro.

  21. Luar Zedlav

    March 26, 2017 at 6:52 pm

    I can't believe I just meet Raul ……. He was so depressing, I didn't know what to say in that moment but to keep it up never give up!!!

  22. Dylans#1Lady

    July 23, 2017 at 8:36 pm

    Who is narrating this episode?

Leave a Reply

Your email address will not be published. Required fields are marked *

Medical Discovery

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Published

on

By



Learn about a recent collaboration with Novartis Pharmaceuticals, which utilizes a deep neural network to accelerate image analysis in early drug discovery by detecting and targeting exactly which cells in the body need treatment.

Read the article:

Keep up to date with the IDZ Weekly Youtube Playlist:

Subscribe to the Intel Software YouTube Channel:

About Intel Software:
The Intel® Developer Zone encourages and supports software developers that are developing applications for Intel hardware and software products. The Intel Software YouTube channel is a place to learn tips and tricks, get the latest news, watch product demos from both Intel, and our many partners across multiple fields. You’ll find videos covering the topics listed below, and to learn more, you can follow the links provided!

Connect with Intel Software:
Visit INTEL SOFTWARE WEBSITE:
Like INTEL SOFTWARE on FACEBOOK:
Follow INTEL SOFTWARE on TWITTER:

INTEL SOFTWARE GITHUB:
INTEL DEVELOPER ZONE LINKEDIN:
INTEL DEVELOPER ZONE INSTAGRAM:
INTEL GAME DEV TWITCH:

IDZ Weekly | Deep Neural Network Acceleration for Image Analysis in Drug Discovery | Intel Software

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Joao Monteiro, MD, PhD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Medical Discovery

Virtual Recap Preview: Stanford Drug Discovery Symposium 2018 – Janet Woodcock, MD

Published

on

By



Virtual Recap: Stanford Drug Discovery 2018
Learn more:

On April 23-24,2018 over 550 people gathered at the Li Ka Shing Conference Center to attend the Third Annual Stanford Drug Discovery Symposium. The event featured a broad range of speakers sharing their expertise in the fields of: academic drug discovery, academic-industry collaboration, science policy, publishing, and research funding. On the first day, the packed-house audience was treated to presentations from academic scientists engaged in groundbreaking research that is laying the foundation for future therapeutic approaches. These included Stanford based Nobel Laureate Brian Kobilka, MD and Edgar Engleman, MD; Kathleen Giacomini, PhD, and Kevan Shokat, PhD from UCSF; and Hugh Rosen, MD, PhD, from the Scripps Research Institute.

Later that afternoon, attendees had the rare opportunity to interact with six top pharmaceutical executives and philanthropists: Ken Frazier, CEO of Merck; Robert Bradway, CEO of Amgen; Joseph Jimenez, former CEO of Novartis; Brent Saunders, CEO of Allergan; Patrick Soon-Shiong, MD, CEO of Nantworks; and Sanford Weill, the Chairman Emeritus of Citigroup and CEO of Casa Rosa Ventures. In this “View from the Top” session moderated by Stanford President Marc Tessier-Lavigne, PhD, the panelists offered their perspectives on drug discovery, including: the future of personalized medicine, the importance of focusing on disease prevention rather than treatment, and the concept that drug pricing could eventually be based on treatment outcomes. The first day ended with the presentation of a Lifetime Achievement Award to Roy Vagelos, MD, former CEO of Merck and current Board chair of Regeneron. Dr. Vagelos was acknowledged in part for his role in leveraging the power of the pharmaceutical industry to make a major impact on global health. During his term as Merck CEO, he personally committed to providing the drug Ivermectin free of charge to anyone in the world for the treatment of elephantiasis and river blindness, with the latter having been since eradicated in multiple Central and South American countries due to Dr. Vagelos’ efforts.

The second day of the Symposium opened with a Keynote address from Janet Woodcock, MD, the Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), who provided a look inside the agency’s new drug regulatory program. This was followed by important presentations about funding priorities from Gary Gibbons, MD, the Director of the National Heart, Lung, and Blood Institute (NHLBI), and Maria Millan, MD, President and CEO of the California Institute for Regenerative Medicine (CIRM). Later, the audience was treated to a panel of editors representing the top publications in biomedical science: the New England Journal of Medicine, Nature Medicine, Science, and the Journal of the American Medical Association. The meeting concluded with a dynamic Shark Tank-style session, in which representatives from eight competitively selected start-up biotechnology companies pitched their ideas to a panel of scientists, venture capitalists, and CEOs. The panelists who provided feedback were: George Scangos, PhD (CEO of Vir), Robert Robbins, MD (President of the University of Arizona), Roy Vagelos, MD, Amy Chang, MSEE (CEO of Accompany), Ram Shriram (Founder of Sherpalo), and Wende Hutton, MBA (General Partner, Canaan). The goal of this session was to have this stellar panel identify strengths and weaknesses of the strategies described in each presentation, providing invaluable advice to these budding entrepreneurs.

The organizers of the meeting, Joseph Wu, MD, PhD; Sanjay Malhotra, PhD; Kuldev Singh, MD; Mark Mercola, PhD; and Chaitan Khosla, PhD, are thrilled with the success of this gathering, and are already looking forward to the next iteration, which will be held April 22-23, 2019.

___

Copyright Keystone Symposia, 2018. All rights reserved.

About Keystone Symposia:
Keystone Symposia is a 501(c)(3) nonprofit organization founded in 1972 that convenes 50-60 open, international scientific research conferences each year across the full range of the life sciences – from cardiovascular disease to immunology to neurobiology. The conferences accelerate life science discovery by bringing together and fostering collaboration among the world’s leading and next generation of research scientists.

Visit Keystone Symposia at:

Visit Virtual Keystone Symposia at:

For more videos:

Follow us on Twitter:

Like us on Facebook:

Link to us on LinkedIn:

Outro music:
“Slider” by Blue Dot Sessions (

Continue Reading

Trending